Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Conditions

Breast Neoplasms 4 Pain, Postoperative 3 Spondylitis, Ankylosing 2 Pain 2 Neoplasms 2 Lung Neoplasms 2 Colonic Neoplasms 2 Agnosia 2 Uterine Cervical Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Sexual Dysfunction, Physiological 1 Pituitary Neoplasms 1 Ovarian Neoplasms 1 Neoplasm, Residual 1 Mucositis 1 Lymphoma, Follicular 1 Inflammation 1 Head and Neck Neoplasms 1 Endometrial Neoplasms 1 Chronic Pain 1 Carcinoma, Non-Small-Cell Lung 1 Arthritis, Rheumatoid 1 Arthritis, Psoriatic 1 Anastomotic Leak 1 Adenocarcinoma of Lung 1 Acute Pain 1

Interventions

Cyclophosphamide 23 blinatumomab 18 Cytarabine 16 fludarabine 13 Azacitidine 12 venetoclax 10 fludarabine phosphate 10 Rituximab 8 Blood Specimen Collection 8 Methotrexate 7 Lenalidomide 7 Dexamethasone 7 Daunorubicin 7 Mercaptopurine 6 Vincristine 5 daratumumab 4 Whole-Body Irradiation 4 Melphalan 4 Idarubicin 4 Etoposide 4 Drug Therapy 4 Busulfan 4 pembrolizumab 3 obinutuzumab 3 Radiotherapy 3 Neoadjuvant Therapy 3 Maintenance 3 Liquid Biopsy 3 Immunotherapy, Adoptive 3 Imatinib Mesylate 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasm, Residual × Anti-Inflammatory Agents, Non-Steroidal × Clear all

NCT03330769 2019-04-17

UPSTREAM

University of Cagliari

Arthritis, Psoriatic, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon ⚡